These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
763 related articles for article (PubMed ID: 2563951)
1. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Rachmilewitz D BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951 [TBL] [Abstract][Full Text] [Related]
2. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Rutgeerts P Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483 [TBL] [Abstract][Full Text] [Related]
4. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139 [TBL] [Abstract][Full Text] [Related]
5. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Brogden RN; Sorkin EM Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592 [TBL] [Abstract][Full Text] [Related]
6. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis? Nakshabendi IM; Duncan A; Russell RI Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343 [TBL] [Abstract][Full Text] [Related]
7. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382 [TBL] [Abstract][Full Text] [Related]
8. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512 [TBL] [Abstract][Full Text] [Related]
9. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine. Donald IP; Wilkinson SP Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480 [TBL] [Abstract][Full Text] [Related]
10. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Habal FM; Greenberg GR Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391 [TBL] [Abstract][Full Text] [Related]
11. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med; 1996 Jan; 124(2):204-11. PubMed ID: 8533995 [TBL] [Abstract][Full Text] [Related]
12. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Rao SS; Cann PA; Holdsworth CD Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724 [TBL] [Abstract][Full Text] [Related]
13. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868 [TBL] [Abstract][Full Text] [Related]